COVID-19 and Neuroimmunological Disorders

Choi, Seok-Jin; Baek, Seol-Hee; Yang, Jiwon; Huh, So-Young; Park, Kee Hong; Kim, Sang Beom; Kim, Ko Woon; Park, Su-Yeon; Sohn, Sung-Yeon; Oh, Jung-Hwan; Shin, Je-Young; Kim, Jee-Eun; Ahn, Suk-Won

J Mult Scler Neuroimmunol > Volume 11(1); 2020 > Article

Review Article

Journal of Multiple Sclerosis and Neuroimmunology 2020;11(1):1-13.
Published online March 1, 2020.

COVID-19와 신경면역질환

최석진, 백설희^a, 양지원^b, 허소영^c, 박기홍^d, 김상범^e, 김고운^f, 박수연^g, 손성연^h, 오정환ⁱ, 신제영^j, 김지은^k, 안석원^l

인하대학교 의과대학 신경과학교실
^a고려대학교 안암병원 신경과
^b가천대학교 길병원 신경과

COVID-19 and Neuroimmunological Disorders

Seok-Jin Choi, Seol-Hee Baek^a, Jiwon Yang^b, So-Young Huh^c, Kee Hong Park^d, Sang Beom Kim^e, Ko Woon Kim^f, Su-Yeon Park^g, Sung-Yeon Sohn^h, Jung-Hwan Ohⁱ, Je-Young Shin^j, Jee-Eun Kim^k, Suk-Won Ahn^l

Department of Neurology, Inha University School of Medicine, Incheon, Korea
^aDepartment of Neurology, Korea University Anam Hospital, Seoul, Korea
^bDepartment of Neurology, Gachon University Gil Medical Center, Incheon, Korea

Abstract

"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19) emerged in December 2019. Unfortunately, the World Health Organization declared COVID-19 a pandemic on March 2020. The pulmonary manifestations of COVID-19 have been well-described, and neurological manifestations including headache, anosmia, altered consciousness, stroke, and post-infectious autoimmunity, are being increasingly recognized. Furthermore, the COVID-19 pandemic is concerning for patients with neuroimmunological disorders who are receiving immunotherapy. It is not known if immunosuppression increases the risk of SARS-CoV-2 infection or worsens infection severity.Although national and international medical societies have developed several guidelines and statements, there is no consensus on neurological immunotherapy in COVID-19 patients. In this Review, we aimed to summarize international recommendations or currently available published reports, and provide management approaches to neurological immunotherapy in the COVID-19 era.
Journal of Multiple Sclerosis and Neuroimmunology 11(1):1-13, 2020"

Key Words: COVID-19, SARS-CoV-2, Neurology, Immunology, Immunotherapy